p.121 抽出テキスト
with increased left ventricular wall thickness. Eur Heart J 2016;37:1826–1834. https:// doi.org/10.1093/eurheartj/ehv583 1059. Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017;38:2879–2887. https://doi.org/10.1093/eurheartj/ehx350 1060. Asif T, Gomez J, Singh V, Doukky R, Nedeltcheva A, Malhotra S. Comparison of planar with tomographic pyrophosphate scintigraphy for transthyretin cardiac amyloidosis: perils and pitfalls. J Nucl Cardiol 2021;28:104–111. https://doi.org/10.1007/ s12350-020-02328-5 1061. Maestro-Benedicto A, Vela P, de Frutos F, Mora N, Pomares A, Gonzalez-Vioque E, et al. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy. Eur J Heart Fail 2022;24:2367–2373. https://doi.org/ 10.1002/ejhf.2658 1062. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009; 120:1203–1212. https://doi.org/10.1161/CIRCULATIONAHA.108.843334 1063. Lopez-Sainz A, Hernandez-Hernandez A, Gonzalez-Lopez E, Dominguez F, Restrepo-Cordoba MA, Cobo-Marcos M, et al. Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center. Rev Esp Cardiol (Engl Ed) 2021;74: 149–158. https://doi.org/10.1016/j.rec.2019.12.020 1064. Bianchi G, Zhang Y, Comenzo RL. AL amyloidosis: current chemotherapy and immune therapy treatment strategies: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 2021;3:467–487. https://doi.org/10.1016/j.jaccao.2021.09. 003 1065. Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J 2012;164:222–228.e1. https://doi.org/10.1016/j.ahj.2012.04. 015 1066. Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 2016;68:1014–1020. https://doi.org/10.1016/j.jacc.2016. 06.033 1067. Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018;39: 2799–2806. https://doi.org/10.1093/eurheartj/ehx589 1068. Cheng RK, Levy WC, Vasbinder A, Teruya S, De Los Santos J, Leedy D, et al. Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis. JACC CardioOncol 2020;2:414–424. https://doi. org/10.1016/j.jaccao.2020.06.007 1069. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989–995. https://doi.org/ 10.1200/JCO.2011.38.5724 1070. Lilleness B, Ruberg FL, Mussinelli R, Doros G, Sanchorawala V. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood 2019;133:215–223. https://doi.org/10.1182/blood-2018-06- 858951 1071. Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK. ATTR amyloidosis: current and emerging management strategies: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 2021;3:488–505. https://doi.org/10. 1016/j.jaccao.2021.06.006 1072. Aimo A, Vergaro G, Castiglione V, Rapezzi C, Emdin M. Safety and tolerability of neurohormonal antagonism in cardiac amyloidosis. Eur J Intern Med 2020;80:66–72. https://doi.org/10.1016/j.ejim.2020.05.015 1073. Mitrani LR, De Los Santos J, Driggin E, Kogan R, Helmke S, Goldsmith J, et al. Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding. Amyloid 2021;28:30–34. https://doi.org/10. 1080/13506129.2020.1810010 1074. Rehorn MR, Loungani RS, Black-Maier E, Coniglio AC, Karra R, Pokorney SD, et al. Cardiac implantable electronic devices: a window into the evolution of conduction disease in cardiac amyloidosis. JACC Clin Electrophysiol 2020;6:1144–1154. https:// doi.org/10.1016/j.jacep.2020.04.020 1075. Rapezzi C, Lorenzini M, Longhi S, Milandri A, Gagliardi C, Bartolomei I, et al. Cardiac amyloidosis: the great pretender. Heart Fail Rev 2015;20:117–124. https://doi.org/10. 1007/s10741-015-9480-0 1076. Higgins AY, Annapureddy AR, Wang Y, Minges KE, Lampert R, Rosenfeld LE, et al. Survival following implantable cardioverter-defibrillator implantation in patients with amyloid cardiomyopathy. J Am Heart Assoc 2020;9:e016038. https://doi.org/10. 1161/JAHA.120.016038 1077. Kim EJ, Holmes BB, Huang S, Lugo R, Al Aboud A, Goodman S, et al. Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator. Europace 2020;22:1216–1223. https://doi.org/10.1093/europace/euaa094 1078. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007–1016. https://doi.org/10.1056/NEJMoa1805689 1078a. Garcia-Pavia P, Aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen AV, et al. Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. N Engl J Med 2023. https://doi.org/10.1056/NEJMoa2303765. Online ahead of print. 1079. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA 2001;286:1218–1227. https://doi.org/10.1001/jama.286.10.1218 1080. Pescatello LS, Franklin BA, Fagard R, Farquhar WB, Kelley GA, Ray CA, et al. Exercise and hypertension. Med Sci Sports Exerc 2004;36:533–553. https://doi.org/10.1249/01. MSS.0000115224.88514.3A 1081. Kelley GA, Kelley KS, Tran ZV. Walking, lipids, and lipoproteins: a meta-analysis of randomized controlled trials. Prev Med 2004;38:651–661. https://doi.org/10.1016/j. ypmed.2003.12.012 1082. Morris JN, Heady JA, Raffle PA, Roberts CG, Parks JW. Coronary heart-disease and physical activity of work. Lancet 1953;262:1053–1057. https://doi.org/10.1016/ S0140-6736(53)90665-5 1083. Tanasescu M, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Exercise type and intensity in relation to coronary heart disease in men. JAMA 2002;288: 1994–2000. https://doi.org/10.1001/jama.288.16.1994 1084. Clausen JSR, Marott JL, Holtermann A, Gyntelberg F, Jensen MT. Midlife cardiorespiratory fitness and the long-term risk of mortality: 46 years of follow-up. J Am Coll Cardiol 2018;72:987–995. https://doi.org/10.1016/j.jacc.2018.06.045 1085. Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, et al. Physical activity and risk of breast cancer, colon cancer, diabetes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013. BMJ 2016;354:i3857. https://doi.org/10. 1136/bmj.i3857 1086. Kim K, Choi S, Hwang SE, Son JS, Lee J-K, Oh J, et al. Changes in exercise frequency and cardiovascular outcomes in older adults. Eur Heart J 2020;41:1490–1499. https:// doi.org/10.1093/eurheartj/ehz768 1087. Lee IM. Physical activity and cancer prevention–data from epidemiologic studies. Med Sci Sports Exerc 2003;35:1823–1827. https://doi.org/10.1249/01.MSS.0000093620. 27893.23 1088. Siscovick DS, Weiss NS, Fletcher RH, Lasky T. The incidence of primary cardiac arrest during vigorous exercise. N Engl J Med 1984;311:874–877. https://doi.org/10.1056/ NEJM198410043111402 1089. Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Muller JE. Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction Onset Study Investigators. N Engl J Med 1993;329:1677–1683. https://doi.org/10.1056/ NEJM199312023292301 1090. Marijon E, Tafflet M, Celermajer DS, Dumas F, Perier M-C, Mustafic H, et al. Sports-related sudden death in the general population. Circulation 2011;124: 672–681. https://doi.org/10.1161/CIRCULATIONAHA.110.008979 1091. Kim JH, Malhotra R, Chiampas G, d’Hemecourt P, Troyanos C, Cianca J, et al. Cardiac arrest during long-distance running races. N Engl J Med 2012;366:130–140. https:// doi.org/10.1056/NEJMoa1106468 1092. Maron BJ, Rowin EJ, Maron MS. Letter by Maron et al. regarding article, “Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)”. Circulation 2019;139: 1557–1558. https://doi.org/10.1161/CIRCULATIONAHA.118.038189 1093. Peterson DF, Siebert DM, Kucera KL, Thomas LC, Maleszewski JJ, Lopez-Anderson M, et al. Etiology of sudden cardiac arrest and death in US competitive athletes: a 2-year prospective surveillance study. Clin J Sport Med 2020;30:305–314. https:// doi.org/10.1097/JSM.0000000000000598 1094. Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med 1998;339:364–369. https://doi.org/10.1056/ NEJM199808063390602 1095. Holst AG, Winkel BG, Theilade J, Kristensen IB, Thomsen JL, Ottesen GL, et al. Incidence and etiology of sports-related sudden cardiac death in Denmark–implications for preparticipation screening. Heart Rhythm 2010;7:1365–1371. https://doi. org/10.1016/j.hrthm.2010.05.021 1096. Maron BJ, Isner JM, McKenna WJ. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. J Am Coll Cardiol 1994;24:880–885. https://doi. org/10.1016/0735-1097(94)90844-3 1097. Maron BJ, Zipes DP. Introduction: eligibility recommendations for competitive athletes with cardiovascular abnormalities–general considerations. J Am Coll Cardiol 2005;45:1318–1321. https://doi.org/10.1016/j.jacc.2005.02.006 1098. Maron BJ, Harris KM, Thompson PD, Eichner ER, Steinberg MH. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 14: Sickle Cell Trait: A Scientific Statement From the ESC Guidelines 3623 Downloaded from academic.oup.com/eurheartj/article/44/37/3503/7246608 by guest on 07 October 2026